Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

苯达莫司汀 医学 美罗华 氟达拉滨 套细胞淋巴瘤 内科学 打开标签 肿瘤科 淋巴瘤 化疗 临床试验 环磷酰胺
作者
Mathias Rummel,Ulrich Kaiser,Christina Balser,Martina Stauch,Wolfram Brugger,Manfred Welslau,N. Niederle,Christoph Losem,Hans-Peter Boeck,Eckhart Weidmann,Ulrich von Gruenhagen,Lothar Mueller,Michael Sandherr,Lars Hahn,Julia Vereshchagina,Frank Kauff,Wolfgang Blau,Axel Hinke,Juergen Barth
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:17 (1): 57-66 被引量:153
标识
DOI:10.1016/s1470-2045(15)00447-7
摘要

Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after alkylating chemotherapy. We aimed to compare the efficacy and safety of rituximab with bendamustine or fludarabine in patients with relapsed, indolent, non-Hodgkin lymphoma and mantle-cell lymphoma.For this randomised, non-inferiority, open-label, phase 3 trial, we recruited patients from 55 centres in Germany, who were subsequently randomised centrally according to prespecified randomisation lists with permuted blocks of randomly variable block size to rituximab (375 mg/m(2), day 1) plus either bendamustine (90 mg/m(2), days 1 and 2) or fludarabine (25 mg/m(2), days 1-3) every 28 days for a maximum of six 28-day cycles. Patients were aged 18 years or older with a WHO performance status of 0-2 and had relapsed or refractory indolent or mantle-cell lymphoma; patients refractory to regimens that included rituximab, bendamustine, or purine analogue drugs were excluded. Patients were stratified by histological subtypes of lymphoma and by their latest previous therapies. Treatment allocation was not masked. The primary endpoint was progression-free survival and the final analysis was completed per protocol. Non-inferiority of bendamustine plus rituximab versus fludarabine plus rituximab was defined as a difference of less than 15% in 1-year progression-free survival. The protocol was amended in July, 2006, after approval of rituximab maintenance (375 mg/m(2) every 3 months for up to 2 years), which was then given to patients achieving a response to either trial treatment. This study is registered with ClinicalTrials.gov, number NCT01456351 (closed to enrolment, follow-up is ongoing).Between Oct 8, 2003, and Aug 5, 2010, we randomly assigned 230 patients to treatment groups (116 bendamustine plus rituximab, 114 fludarabine plus rituximab). 11 patients were excluded for protocol violations and were not followed up further (two in the bendamustine plus rituximab group and nine in the fludarabine plus rituximab group). Thus, 219 patients were included in the per-protocol analysis (114 bendamustine plus rituximab, 105 fludarabine plus rituximab). 1-year progression-free survival with bendamustine plus rituximab was 0·76 (95% CI 0·68-0·84) and 0·48 (0·39-0·58) with fludarabine plus rituximab (non-inferiority p<0·0001). At a median follow-up of 96 months (IQR 73·2-112·9), median progression-free survival with bendamustine plus rituximab was 34·2 months (95% CI 23·5-52·7) and 11·7 months (8·0-16·1) with fludarabine plus rituximab (hazard ratio [HR] 0·54 [95% CI 0·38-0·72], log-rank test p<0·0001). Safety outcomes were similar in both groups, with 46 serious adverse events recorded (23 in the bendamustine plus rituximab group and 23 in the fludarabine plus rituximab group), most commonly myelosuppression and infections.In combination with rituximab, bendamustine was more effective than fludarabine, suggesting that bendamustine plus rituximab may be the preferred treatment option for patients with relapsed indolent and mantle-cell lymphomas.Roche Pharma AG, Ribosepharm GmbH, Mundipharma GmbH, Studiengruppe indolente Lymphome (StiL).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
琪琪发布了新的文献求助10
1秒前
1秒前
丘比特的应助被斯文曼波采纳,获得10
2秒前
QQ2完成签到,获得积分10
2秒前
小熊星星发布了新的文献求助10
2秒前
HUANG发布了新的文献求助10
2秒前
3秒前
本色风情发布了新的文献求助10
3秒前
无极微光的应助被现代书雪采纳,获得20
3秒前
芝麻汤圆完成签到,获得积分10
4秒前
xiaoxu小徐发布了新的文献求助10
4秒前
科目三的应助被健壮的涑采纳,获得10
4秒前
4秒前
5秒前
墨凡完成签到,获得积分10
5秒前
饺子发布了新的文献求助10
5秒前
高永康发布了新的文献求助20
5秒前
FashionBoy的应助被CJX采纳,获得10
5秒前
6秒前
ROSEANNE完成签到,获得积分10
6秒前
6秒前
王晨发布了新的文献求助10
6秒前
6秒前
jingjingzi完成签到,获得积分10
6秒前
Nole的应助被顺顺采纳,获得10
7秒前
7秒前
LuckyYu发布了新的文献求助10
7秒前
孙倩倩发布了新的文献求助10
7秒前
7秒前
wonderful完成签到,获得积分10
7秒前
7秒前
8秒前
忆雪完成签到,获得积分10
9秒前
10秒前
种花家完成签到,获得积分10
10秒前
10秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187918
求助须知:如何正确求助?哪些是违规求助? 9575850
关于积分的说明 21843829
捐赠科研通 7785760
什么是DOI,文献DOI怎么找? 3435128
关于科研通互助平台的介绍 2559501
邀请新用户注册赠送积分活动 2482027